Department of Pharmacology, Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Pharmacy of Beijing Chest Hospital affiliated to The Capital Medical University, Beijing, China.
Int J Antimicrob Agents. 2014 Feb;43(2):148-53. doi: 10.1016/j.ijantimicag.2013.10.010. Epub 2013 Nov 13.
The objective of the present study was to compare the activities of regimens containing linezolid (LZD) with those not containing LZD against Mycobacterium tuberculosis infection in mice. The three regimens excluding LZD selected in this study are often used in practice against multidrug-resistant tuberculosis (MDR-TB). When LZD was added to these MDR-TB regimens, the combinations were significantly more active after 2 months of therapy with regard to lung CFU reductions. The activity of LZD-containing regimens was greater than the World Health Organization's standard first-line regimen of rifampicin+isoniazid+pyrazinamide. In particular, when LZD was included in the combination levofloxacin+amikacin+para-aminosalicylic acid+pyrazinamide+clofazimine, culture negativity of the lungs was reached after 2 months of treatment in every case. In addition, the serum levels of interleukin-10 and interferon-γ of mice were determined and were found not to be surrogate markers of bacterial clearance.
本研究的目的是比较含利奈唑胺（LZD）和不含 LZD 的方案在小鼠结核分枝杆菌感染中的活性。本研究中选择的三种不含 LZD 的方案在实践中常用于治疗耐多药结核病（MDR-TB）。当 LZD 加入这些 MDR-TB 方案中时，在 2 个月的治疗后，肺 CFU 减少方面，联合治疗的活性显著更高。含 LZD 方案的活性大于世界卫生组织的利福平+异烟肼+吡嗪酰胺+左氧氟沙星+阿米卡星+对氨基水杨酸+克拉霉素+氯法齐明标准一线方案。特别是，当 LZD 包含在左氧氟沙星+阿米卡星+对氨基水杨酸+吡嗪酰胺+氯法齐明联合方案中时，在治疗 2 个月后，所有小鼠的肺部培养均转为阴性。此外，还测定了小鼠的白细胞介素-10 和干扰素-γ血清水平，发现它们不是细菌清除的替代标志物。
Zotero 插件